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ABSTRACT:  Mammalian  Nod2  is  an  intracellular  protein 
that is implicated in the innate immune response to the bacte-
rial  cell  wall  and  is  associated  with  the  development  of 
Crohn’s disease, Blau syndrome and gastrointestinal cancers.  
Nod2 is required for an immune response to muramyl dipep-
tide (MDP), an immunostimulatory fragment of bacterial cell 
wall, but it is not known if MDP binds directly to Nod2.  We 
report the expression and purification of human Nod2 from 
insect  cells.  Using  novel  MDP-self-assembled  monolayers 
(SAMs) we provide the first biochemical evidence for a direct, 
high affinity interaction between Nod2 and MDP.  
The innate immune system is the body’s first line of defense 
against  invading  pathogens 
1,2.  This  ancient  system  has 
evolved to exist in a symbiotic relationship with commensal 
bacteria and at the same time to recognize and destroy virulent 
bacteria 
1-3.  Chronic  inflammatory  diseases  such  as  asthma, 
rheumatoid arthritis, and Crohn’s disease are thought to arise 
from an inappropriate innate immune response to bacteria 
4-9. 
Chronic inflammation has also been shown to lead to a variety 
of  types  of  cancers  including  those  affecting  gastric,  colon, 
and lung 
10.  
Mammalian Nod2 is an intracellular protein that is involved 
in the signaling response to bacterial cell wall fragments 
11,12. 
Mutations in Nod2 correlate with the development of Crohn’s 
disease, a chronic inflammatory disease of the gastrointestinal 
tract 
13-15.  In  order  to  generate  the  proper  immunologic  re-
sponse, the Nod2 signaling pathway must recognize bacteria.  
The biochemical mechanism by which Nod2 detects bacteria 
is not known, but it has been proposed that Nod2 senses bacte-
rial cell wall fragments directly. Nod2 could sense bacterial 
cell wall fragments through at least three mechanisms:  (1) a 
direct interaction; (2) a mediated interaction; or (3) a signaling 
relay.  The mechanism of activation remains unresolved be-
cause until now the proper tools to probe the mechanism have 
been unavailable. 
Nod2 is essential for the cellular response to a small frag-
ment of bacterial cell wall, muramyl dipeptide, consisting of 
one carbohydrate and two amino acids (MDP-(D), 1, Figure 1) 
12,16. MDP is found in both Gram-negative and Gram-positive 
bacteria.  Cellular and in vivo assays have shown that when 
mammalian cells expressing Nod2 are treated with MDP, an 
inflammatory response is activated via the NF-kB and MAP 
kinase pathways 
17-20. Moreover, the response is not observed 
if a diastereomer of 1, (MDP-(L), 2, Figure 1), is used in the 
cellular assays. For this reason, MDP is often referred to in the 
literature as the “ligand” for Nod2 signaling
21.  However, there 
is  no  biochemical  or  biophysical  data  that  demonstrates  an 
interaction between the two molecules 
22. The purpose of our 
investigation was to determine if Nod2 and MDP interact in 
vitro.  We developed an expression system and a biochemical 
assay using synthetic probes to investigate this question.   
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Figure 1:  Muramyl Dipeptides:  MDP-(D) is the biologically rele-
vant isomer;  MDP-(L) is a synthetic diastereomer of the com-
pound found in Nature.  
Human  Nod2  is  a  large  protein  (1040  residues,  110  kD) 
with  multiple  domains:  two  N-terminal  caspase  recruitment 
domains  (CARDs),  a  central  nucleotide  oligomerization  do-
main (NOD) and a C-terminal leucine rich repeat (LRR) do-
main 
16.  To determine if Nod2 interacts directly with MDP we 
first expressed a Flag-tagged version of Nod2 using baculovi-
rus-infected Sf21 cells (Figure S1a in the Supporting Infor-
mation) with a yield of 1 mg/L. CD spectroscopy and limited 
proteolysis experiments are consistent with Nod2 being a fold-
ed  protein  (Figure  S1b  and  S1c  in  the  Supporting  Infor-
mation). 
With purified Nod2 in hand, a Surface Plasmon Resonance 
(SPR) assay was developed to assess binding to MDP. Initial 
attempts  to  develop  a  SPR  assay  with  biotinylated-MDP
23 
failed,  as  we  observed  significant  non-specific  binding  of 
Nod2 to the streptavidin/biotin chip lacking MDP (Figure S2).  
In order to develop a SPR assay, we coupled 6-amino MDP (3 
& 4, Figure 1) directly to the chip without the use of biotin.  3 
& 4 are synthetic intermediates of the biotinylated -MDPs and 
have been shown to activate Nod2 in the appropriate manner
23.  
Using methodology developed by Whitesides and co-workers, 
we prepared carboxy-terminated  alkane  thiol self assembled 
monolayers (SAMs) and then used on-chip NHS/EDC activa-
tion of the carboxylic acid (Figure 2) 
24 to couple 6-amino-
MDPs to the chip surface.    
A  typical  SPR  assay  uses  four  sensor  lanes  on  a  single 
chip
25.  In the assay, we included two controls:  (1) the iso-
glutamine diastereomer of MDP (4, Figure 1) that does not 
activate  the  Nod2  pathway  and  (2)  an  ethanolamine-capped 
monolayer (Figure 2). A typical assay setup involved flowing 
Nod2 over each lane of the sensor chip and observing changes 
in resonance units (RU).  The assay was robust and allowed 
the screening of a wide variety of conditions.  There was lower 
background binding of Nod2 to the synthetic chip as compared 
to the biotin chip (Figure S2 and S3).    
S
O
O
O
HO
S
O
O
O
HO
S
O
O
O
S
O
O
O
HO
1) NHS, EDC;
2) 3, 4, or ethanolamine
Carboxylic Acid MDP - Chip
3-Lane:  R =  
4-Lane:  R = 
 
Control-Lane:  R = CH2CH2OH
O
O
O
O
HO
O
S
O
O
O
HO
S
O
O
O
HO
S
O
O
O
S
O
O
O
HO O
O
O
O
HN
O
O
NHAc
HO
O
O
H
N
O
NH
O
O NH2
OH
OH
R
O
NHAc
HO
O
O
H
N
O
NH
O
O NH2
OH
OH
 
Figure 2:  Synthesis of the MDP Chip:  A mixed SAM consisting 
of  1%  mole  fraction  of  hexa(ethylene  glycol)-carboxylic  acid 
(EG)6CO2H)-terminated thiol in tri(ethylene glycol) ((EG)3OH)-
terminated thiol was prepared.  The carboxylic acid groups were 
then activated with NHS and EDC to form the NHS ester.  Dis-
placement of the NHS ester with the amino group of MDP afford-
ed the formation of an amide bond.  Excess NHS esters were de-
activated with ethanolamine.  
Nod2 bound to MDP with high affinity (Figure 3). The bio-
logically active MDP, 3-Lane, bound to Nod2 with a KD of 51 
nM ± 18. Surprisingly, we found that Nod2 was able to bind to 
both isomers of MDP (Figure 3), as Nod2 bound to the 4-Lane 
with a KD of 150 nM ± 24, which is only slightly higher than 
the KD observed for the 3-Lane.  Thus, the iso-glutamine ste-
reochemistry is not a key recognition determinant.  To demon-
strate that binding of Nod2 to the MDP-chip is indeed specific, 
a  competition  study  was  performed.    When  Nod2  was  pre-
treated with either 3 or 4, diminished binding to the chip was 
observed  (Figure  4).  Encouragingly,  the  competition  data 
show the same trend as the on-chip data, i.e. the free D-isomer 
of MDP is a better competitor than the free L-isomer. These 
data suggest that Nod2 senses bacterial cell wall fragments by 
binding directly to them. 
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Figure 3: Nod2 binds to MDP: 3 and 4 bind to MDP with high 
affinities.  Nod2 (pH 6.0) was applied to the MDP-Chip at varying 
concentrations at a rate of 3 mL min
-1.  After ten minutes, the 
resonance  signal  was  recorded,  ethanolamine  background  was 
subtracted from the experimental signal and plotted. The data was 
fitted to a standard one site binding model by non-linear regres-
sion analysis using Prism 4 (GraphPad). 
 
Figure 4:  Binding of Nod2 to the MDP-chip is specific.  Nod2 
(pH 5.5, 0.5 µM, either in the presence or absence of free MDP (1 
µM)) was applied to the MDP-Chip.  The relative resonance sig-
nal was recorded after ten minutes.    
At low concentrations the MDP isomers 2 and 4 do not acti-
vate  the  NF-κB  response  via Nod2  in  cellular  assays 
18,23. 
However, we show that MDP-(L) is able to activate the path-
way at higher concentrations using the established cellular NF-
kB luciferase reporter assay and transfected Nod2 (Figure 5).  
The NF-kB activation observed in the absence of transfected 
Nod2 DNA is the result of low levels of endogenous Nod2 in 
Hek293T cells
26.  The cellular assay results demonstrate that 
both  isomers of MDP are able to activate the Nod2/NF-kB 
pathway, which is consistent with the binding data showing 
that Nod2 can bind one isomer better than the other. Cellular 
potencies often do not exactly match their in vitro KDs 
27,28. 
We find the cellular activation parallels in vitro binding but at 
slightly  lower  potency.   
 
Figure 5: 2 (MDP - (L)) activates the Nod2/NF-kB pathway at 
higher concentrations.  Hek293T cells were transfected with 
(±Nod DNA (0.1 ng), NF-κB reporter, and a Renilla control.  
The cells were treated with stimuli for 12h, harvested and test-
ed for luciferase activity.   
The in vitro interaction between Nod2 and MDP is depend-
ent on pH (Figure 6), with the pH range from 5.0 to 6.5 giving 
maximal binding.  The data suggest that in vivo binding could 
occur in an acidic cellular compartment, a model supported by 
cellular  assays  that  show  pH-dependent  internalization  of 
MDP 
29,30. Girardin and coworkers show that the internaliza-
tion of MDP is optimal in the pH range of 5.5 to 6.5, which 
corresponds with the MDP/Nod2 binding data.   
Nod2 is predicted to have ATP binding capabilities, as it has 
Walker A and Walker B regions 
31.  The ATP binding capaci-
ties of the protein have been suggested to be important for  
oligomerization,  protein-protein  interactions  and  subsequent 
activation
32.   To test if the nucleotide binding was necessary 
for Nod2 to bind to MDP, we measured Nod2 binding to MDP 
±ATP/ADP.  Nod2 binds with no appreciable change to MDP 
in the presence and absence of 10 µM ATP/ADP (Figure 6), 
suggesting that ATP/ADP is not necessary for Nod2 to bind to 
MDP.  
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Figure 6:  Nod2/MDPs interact under a variety of conditions.  The 
pH of Nod2 was adjusted before application to the MDP-Chip. 
Nod2 was pre-incubated with 10 µM ATP or ADP before applica-
tion to the MDP-Chip.  The relative resonance signal was record-
ed after ten minutes.    
 Prior to our investigation, the mechanism of Nod2 activa-
tion of NF-κB by treatment with MDP was unclear.  We have 
taken a biochemical approach to demonstrate that Nod2 binds 
directly to bacterial cell wall fragments. Recombinant Nod2 
and the synthetic MDP tools allowed for the development of in 
vitro assay to detect binding.  The assay that we have devel-
oped  will  be  a  valuable  asset  in  screening  for  inhibi-
tors/activators of the Nod2 signaling pathway and determining 
if Nod2 is able to differentiate commensal versus pathogenic 
bacteria.  In addition, the assay will be useful in determining 
the  Nod2  Crohn’s  mutants  are  capable  of  binding  to  MDP.   
This is the first biochemical evidence to show an interaction 
between  the  two  molecules,  and  establishes  that  MDP  is  a 
high-affinity ligand for Nod2.  
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